DOSIsoft Unveils DOSIsoft Theranostics for Advanced Personalized Nuclear Medicine Solutions

DOSIsoft Launches DOSIsoft Theranostics

DOSIsoft, a prominent player in dosimetry software for radiation oncology and nuclear medicine, has officially announced the creation of DOSIsoft Theranostics, aimed at propelling software innovation within the realm of personalized nuclear medicine and theranostics. This launch comes just ahead of the upcoming SNMMI 2026 event.

The new entity is designed to focus solely on the development of theranostic software solutions, facilitating their widespread adoption in clinical settings. By positioning itself as an independent and trustworthy software partner, DOSIsoft Theranostics intends to collaborate comprehensively with the entire clinical and industrial ecosystem, underlining its commitment to fostering innovative practices and technologies.

A Commitment to Innovation

Marc Uszynski, CEO of DOSIsoft, expressed that, "The establishment of a dedicated entity for theranostics reflects our long-term commitment to this rapidly developing field. It provides DOSIsoft Theranostics the strategic focus and agility required to accelerate innovation, forge new partnerships, and enhance the global adoption of theranostic applications."

Theranostics, which combines diagnostics with targeted therapy, ushers in a new era of highly personalized medicine. As the market for nuclear medicine evolves, DOSIsoft Theranostics aims to lead by employing advanced AI-driven workflows and quantitative imaging techniques that enhance patient-specific treatment strategies.

With over 20 years of experience backing its initiative, DOSIsoft Theranostics leverages the robust credibility built by its parent company. The formation of this new entity is a strategic move aimed at boosting innovation in radiopharmaceutical therapies while also adapting to the ever-growing needs of clinical practice.

Advanced Tools for Enhanced Patient Care

DOSIsoft Theranostics will harness cutting-edge software tools and scientific expertise to drive advancements in clinical research and innovation. A centerpiece of this initiative is PLANET®, a flagship product that has evolved from its roots in external beam treatment planning. This versatile and comprehensive platform supports multi-radionuclides and includes functionalities for personalized dosimetry on a voxel scale and multimodal interoperability, meeting modern diagnostic and therapeutic complexities head-on.

PLANET® has already gained regulatory approval, including the FDA's 510(k) clearance and CE marking (MDR), and is actively being used in numerous hospitals and academic centers globally. This independence from specific equipment manufacturers gives clinicians considerable flexibility in managing multiple workflows and therapeutic strategies, thus enhancing care delivery.

Looking Ahead: The Role of DOSIsoft Theranostics in the Future

As DOSIsoft Theranostics prepares to showcase its capabilities at the SNMMI 2026 event, anticipation builds around its potential impact in the field. The specialized focus on theranostics not only underscores DOSIsoft's dedication to improving patient outcomes but also positions it strategically as a linchpin in the ongoing pursuit of personalized medicine.

The launch of DOSIsoft Theranostics is not merely a response to current healthcare trends; it is a proactive step towards shaping the future of nuclear medicine. By facilitating the integration of innovative technologies and comprehensive solutions, DOSIsoft Theranostics aims to transform how nuclear medicine is practiced and experienced around the world.